Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -120% Improvement Relative Risk ICU admission 87% Cereda et al. Vitamin D for COVID-19 Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Prospective study of 129 patients in Italy Higher mortality with higher vitamin D levels (p=0.038) Cereda et al., Clinical Nutrition, doi:10.1016/j.clnu.2020.10.055 Favors vitamin D Favors control
Vitamin D 25OH deficiency in COVID-19 patients admitted to a tertiary referral hospital
Cereda et al., Clinical Nutrition (Edinburgh, Scotland), doi:10.1016/j.clnu.2020.10.055
Cereda et al., Vitamin D 25OH deficiency in COVID-19 patients admitted to a tertiary referral hospital, Clinical Nutrition (Edinburgh, Scotland), doi:10.1016/j.clnu.2020.10.055
Nov 2020   Source   PDF  
  All Studies   Meta
Prospective cohort study of 129 adult hospitalized COVID-19 patients finding patients with vitamin D levels >20ng/mL had increased mortality after adjustment. This study does not account for the risk of having a serious enough case to be hospitalized, and adjustments for factors correlated with vitamin D levels could obscure a potential association with vitamin D levels.
risk of death, 120.0% higher, RR 2.20, p = 0.04, high D levels 10 of 30 (33.3%), low D levels 24 of 99 (24.2%), inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >20ng/mL.
risk of ICU admission, 86.7% lower, RR 0.13, p = 0.59, high D levels 0 of 30 (0.0%), low D levels 5 of 99 (5.1%), NNT 20, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cereda et al., 1 Nov 2020, prospective, Italy, peer-reviewed, 13 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Clinical Nutrition 40 (2021) 2469e2472 Contents lists available at ScienceDirect Clinical Nutrition journal homepage: Short Communication Vitamin D 25OH deficiency in COVID-19 patients admitted to a tertiary referral hospital Emanuele Cereda a, 1, Laura Bogliolo b, 1, Catherine Klersy c, Federica Lobascio a, Sara Masi a, Silvia Crotti a, Ludovico De Stefano b, Raffaele Bruno d, Angelo Guido Corsico e, f, Antonio Di Sabatino g, Stefano Perlini f, h, Carlomaurizio Montecucco b, f, Riccardo Caccialanza a, *, 1, on behalf of the NUTRI-COVID19 IRCCS San Matteo Pavia Collaborative Groupy a Clinical Nutrition and Dietetics Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy c Biometry and Clinical Epidemiology Service, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy d Division of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo and Department of Medical, Surgical, Diagnostic and Paediatric Science, University of Pavia, Pavia, Italy e Pneumology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy f Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy g Department of Internal Medicine, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy h Emergency Medicine Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy b a r t i c l e i n f o s u m m a r y Article history: Received 2 September 2020 Accepted 27 October 2020 Background & aims: Great interest has been raised by the possible protective role of vitamin D in coronavirus disease 2019 (COVID-19), but objective data on 25(OH)vitamin D deficiency in hospitalized COVID-19 patients are not conclusive. The aim of this study was to determine the prevalence of 25(OH)vitamin D deficiency in COVID-19 patients admitted to an Italian referral hospital and explore its association with clinical outcomes and the markers of disease severity. Methods: In this single-center cohort study, 129 consecutive adult COVID-19 patients hospitalized in an Italian referral center were enrolled from March to April 2020. 25(OH)Vitamin D serum levels were assessed 48 h since hospital admission and categorized into: normal (30 ng/mL), insufficient (<30 20 ng/mL), moderately deficient (<20 - 10 ng/mL), severely deficient (<10 ng/mL). Results: The prevalence of 25(OH)vitamin D insufficiency, moderate deficiency and severe deficiency was 13.2%, 22.5% and 54.3%, respectively. 25(OH)Vitamin D deficiency (<20 ng/mL) was not associated with COVID-19 clinical features and outcomes. Unexpectedly, after adjusting for major confounders, a significant positive..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop